CD8A and neoplasm: The strategy was effective in vitro and co-culture of human peripheral blood mononuclear cells (PBMC) and LGR5+ NALM6 (pre-B ALL) tumour cells in the presence of α-LGR5 bispecific led not only to robust CD4+ and CD8+ T-cell activation but also potent and specific tumour cell killing [22].